STOCK TITAN

Immunome, Inc. (IMNM) Revenue by Year

IMNM

Immunome, Inc. generated $6.9M in revenue in fiscal year 2025. This represents a decrease of 23.2% from the prior fiscal year. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Immunome, Inc. has filed alongside them.

FY2025 annual
Revenue $6.9M
YoY -23.2%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

IMNM Revenue by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-K
Revenue$6.9M-23.2%$9.0M-35.5%$14.0MN/AN/AN/AN/A

IMNM Revenue by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Revenue$0-100.0%$0-100.0%N/A$0-100.0%$4.0M+69.8%$2.9M+184.4%$2.7M-28.4%$2.9M-18.4%$2.4M-44.5%$1.0M-56.5%$3.8M$3.6M

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Immunome, Inc. financials

Frequently Asked Questions

What was Immunome, Inc.'s revenue in fiscal year 2025?

Immunome, Inc. generated $6.9M in revenue in fiscal year 2025.

How fast is Immunome, Inc.'s revenue growing?

Immunome, Inc. (IMNM) revenue fell by 23.2% year over year, from $9.0M to $6.9M in fiscal year 2025.

What was Immunome, Inc.'s revenue in the most recent quarter?

Immunome, Inc. (IMNM) reported $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Immunome, Inc. (IMNM) reported on that line in every period on record.